➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Last Updated: February 26, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR LONAFARNIB

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Lonafarnib

Subscribe to access the full database, or Start Trial
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00003956	Combination Chemotherapy in Treating Patients With Advanced Cancer	Completed	National Cancer Institute (NCI)	Phase 1	1999-04-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase I trial to study the effectiveness of SCH 66336, fluorouracil, and leucovorin in treating patients who have advanced cancer.
NCT00003956	Combination Chemotherapy in Treating Patients With Advanced Cancer	Completed	Memorial Sloan Kettering Cancer Center	Phase 1	1999-04-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase I trial to study the effectiveness of SCH 66336, fluorouracil, and leucovorin in treating patients who have advanced cancer.
NCT00005030	SCH 66336 Before Surgery in Treating Patients With Colorectal Cancer That Has Metastasized to the Liver	Withdrawn	National Cancer Institute (NCI)	Phase 1	2000-06-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Randomized phase I trial to compare the effectiveness of different doses of SCH 66336 before surgery in treating patients who have colorectal cancer that has metastasized to the liver.
NCT00005030	SCH 66336 Before Surgery in Treating Patients With Colorectal Cancer That Has Metastasized to the Liver	Withdrawn	M.D. Anderson Cancer Center	Phase 1	2000-06-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Randomized phase I trial to compare the effectiveness of different doses of SCH 66336 before surgery in treating patients who have colorectal cancer that has metastasized to the liver.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for Lonafarnib

Condition Name

Chart
Table

Condition Name for Lonafarnib
Intervention	Trials
Progeria	4
Breast Cancer	4
Hepatitis D	3
Chronic Hepatitis D Infection	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for Lonafarnib
Intervention	Trials
Hepatitis	8
Hepatitis D	8
Hepatitis D, Chronic	6
Progeria	4
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for Lonafarnib

Trials by Country

Map
Table

Trials by Country for Lonafarnib
Location	Trials
United States	24
Turkey	2
Netherlands	2
France	2
Belgium	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for Lonafarnib
Location	Trials
Texas	5
Massachusetts	5
Maryland	3
Ohio	1
Indiana	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for Lonafarnib

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for Lonafarnib
Clinical Trial Phase	Trials
Phase 3	3
Phase 2	16
Phase 1/Phase 2	2
[disabled in preview]	10
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for Lonafarnib
Clinical Trial Phase	Trials
Completed	11
Terminated	8
Recruiting	4
[disabled in preview]	3
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Lonafarnib

Sponsor Name

Chart
Table

Sponsor Name for Lonafarnib
Sponsor	Trials
Schering-Plough	7
National Cancer Institute (NCI)	6
M.D. Anderson Cancer Center	5
[disabled in preview]	5
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for Lonafarnib
Sponsor	Trials
Other	24
Industry	18
NIH	9
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys

AstraZeneca

Boehringer Ingelheim

Johnson and Johnson

Harvard Business School

McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

By using our website you are consenting to our use of cookies in accordance with our privacy policy.